Filing Details

Accession Number:
0001209191-21-071172
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-23 18:58:53
Reporting Period:
2021-12-21
Accepted Time:
2021-12-23 18:58:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818033 Heron Therapeutics Inc. HRTX Pharmaceutical Preparations (2834) 942875566
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1553179 Waage Christian 4242 Campus Point Court
Suite 200
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-12-21 300 $9.73 3,200 No 4 S Direct
Common Stock Acquisiton 2021-12-22 10,452 $0.00 13,652 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2021-12-22 20,903 $0.00 20,903 $9.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,903 2031-12-22 No 4 A Direct
Footnotes
  1. The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 15, 2021. The shares were sold by Mr. Waage to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on December 21, 2021.
  2. The range of sales prices received was $9.625 to $9.945. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  3. The shares were granted as restricted stock units which vest in full on December 22, 2022.
  4. The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.